Title:Selective Inhibitors of Cyclooxygenase-2 (COX-2), Celecoxib and Parecoxib: A Systematic Review

标题：环氧化酶-2 (COX-2) 选择性抑制剂塞来昔布和帕瑞昔布：系统

Authors: J.L. Mateos, et al.

作者：J.L. Mateos 等
Published in: Drugs Today (Barc), February 2010, Volume 46, Supplement A, Pages 1-25

发表期刊：《今日药物》（巴塞罗那），2010年2月，46卷，增刊A，1-25页

Objective:

This systematic review examines the efficacy and safety profiles of COX-2 selective inhibitors, specifically celecoxib and parecoxib. It highlights their anti-inflammatory and analgesic properties and compares their gastrointestinal toxicity to non-selective NSAIDs.

研究目的：

本系统评价研究了COX-2选择性抑制剂，特别是塞来昔布和帕瑞昔布的疗效和安全性。它重点介绍了它们的抗炎和镇痛特性，并将其胃肠道毒性与非选择性NSAIDs进行了比较。

Methodology:

Study Design: Systematic review of randomized controlled trials and observational studies
Data Sources: PubMed, Cochrane Library, and other relevant databases
Selection Criteria: Studies evaluating the efficacy and safety of celecoxib and parecoxib
Outcome Measures: Pain relief, incidence of gastrointestinal side effects, cardiovascular events, and overall safety

方法：

研究设计：随机对照试验和观察性研究的系统评价
数据来源：PubMed，Cochrane图书馆及其他相关数据库
选择标准：评估塞来昔布和帕瑞昔布疗效和安全性的研究
结果测量：疼痛缓解，胃肠道副作用发生率，心血管事件及总体安全性

Key Findings:

1. **Efficacy:** Both celecoxib and parecoxib demonstrated significant pain relief in various clinical settings, including postoperative pain, rheumatoid arthritis, and osteoarthritis.
2. **Safety:** COX-2 inhibitors showed a reduced risk of gastrointestinal side effects compared to traditional NSAIDs. However, there was a noted increase in cardiovascular events, particularly with long-term use.
3. **Tolerability:** Parecoxib was well tolerated with a safety profile similar to that of celecoxib.

主要发现：

1. **疗效：** 塞来昔布和帕瑞昔布在各种临床环境中均显示出显著的疼痛缓解效果，包括术后疼痛，类风湿性关节炎和骨关节炎。
2. **安全性：** 与传统NSAIDs相比，COX-2抑制剂的胃肠道副作用风险较低。然而，长期使用时心血管事件有所增加。
3. **耐受性：** 帕瑞昔布耐受性良好，其安全性与塞来昔布相似。

Conclusion:

Celecoxib and parecoxib are effective COX-2 selective inhibitors with reduced gastrointestinal toxicity compared to non-selective NSAIDs. Despite their efficacy, caution is advised due to the potential increase in cardiovascular risk, especially with prolonged use.

结论：

塞来昔布和帕瑞昔布是有效的COX-2选择性抑制剂，与非选择性NSAIDs相比具有较低的胃肠道毒性。尽管它们有效，但由于可能增加的心血管风险，尤其是长期使用时，需谨慎使用。

CAS Numbers for COX-2 Inhibitors

1.Celecoxib (塞来昔布)

CAS Number: 169590-42-5

2.Parecoxib (帕瑞昔布)

CAS Number: 198470-85-8

3.Rofecoxib (罗非昔布)

CAS Number: 162011-90-7

4.Valdecoxib (伐地考昔)

CAS Number: 181695-72-7

5.Etoricoxib (依托考昔)

CAS Number: 202409-33-4

6.Lumiracoxib (鲁米考昔)

CAS Number: 220991-32-2

7.Meloxicam (美洛昔康)

CAS Number: 71125-38-7